



Post Authorisation Assessments

For details of post authorisation assessments prior to 1st January 2021,
please refer to the [EMA](#) website.

Frontpro 136 mg Chewable Tablets for Dogs >25–50 kg Vm 04491/5010

| | | |
|---|-------------------|--|
| • | 13 October 2023 | Addition of an alternative site responsible for manufacturing of the finished product. Editorial changes in section 3.1.2 are also included. |
| • | 22 August 2023 | Addition of a new supplier of a starting material used in the manufacturing process of the active substance. Addition of a new supplier of a starting material used in the manufacturing process of the active substance. Addition of a new supplier of a starting material used in the manufacturing process of the active substance. |
| • | 06 June 2023 | Change in batch size for intermediate used in the manufacturing process of the active substance. |
| • | 13 April 2023 | Change(s) in the name or address or contact details of a qualified person for pharmacovigilance (QPPV). |
| • | 23 August 2022 | Change in name of manufacturer of the finished product. |
| • | 25 April 2022 | Increase in batch size of the active substance. |
| • | 25 April 2022 | Change in composition of the immediate packaging for the active substance. |
| • | 15 February 2022 | Deletion of a supplier of packaging components or devices. |
| • | 02 September 2021 | Change in shape or dimensions of the container or closure (immediate packaging). Minor change in the manufacturing process of the finished product. Deletion of a non-significant specification parameter of an excipient. |
| • | 25 March 2021 | Change in the QPPV of an existing pharmacovigilance system as described in the DDPS. |